Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.
Fiche publication
Date publication
juillet 2024
Journal
Cancer chemotherapy and pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
Tous les auteurs :
Adenis A, Ghiringhelli F, Gauthier L, Mazard T, Evesque L, Evrard A, Chalbos P, Moussion A, Gourgou S, Ychou M
Lien Pubmed
Résumé
The combination of bevacizumab and FOLFIRINOX is used in patients with RAS-mutant metastatic colorectal cancer (RASm-mCRC). Regorafenib, an oral multi-tyrosine kinase inhibitor, has antiangiogenic properties, cytostatic effects and also true cytotoxic effects, unlike bevacizumab. The aim of this study was to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of the regorafenib-FOLFIRINOX combination in patients with RASm-mCRC.
Mots clés
Colorectal cancer, FOLFIRINOX, Phase 1 trial, Recommended phase 2 dose, Regorafenib
Référence
Cancer Chemother Pharmacol. 2024 07 10;: